Introduction:
Eli Lilly plans to invest US $450 million in a facility in the Research Triangle Park area of the United States, to expand its manufacturing capabilities.
Features:
To meet the growing demand for Lilly's incretin-based diabetes treatments, the expansion includes more parenteral filling, device assembly, and packaging capacity.
The FDA inspections at Research Triangle Park are presently being prepared for, and initial manufacturing is anticipated to begin this year.
This expansion is crucial for ensuring the availability of current Lilly medications and for setting the pharmaceuticals' worldwide distribution.
During this phase of the project, it is anticipated that at least 100 new jobs will be generated, mostly for manufacturing staff who will use cutting-edge technology to produce incretin treatments and medical devices.
The production site's operations are expected to start in 2027.
Specifications:
| Name | Eli Lilly |
| Type | Expansion |
| Budget | US $450 million |
| Year | 2027 |
